Simona Heidempergher

Banca Intermobiliare di Investimenti e Gestioni SpA provides private banking services. It operates through the following business segments: Clients, Finance, Corporate Center, and Non Core. The Client segment covers all typical transactions of private banking such as securities brokerage, management, investment services consulting, distribution of managed savings products through individual and collective asset management portfolios, and ancillary activities such as lending and corporate advisory services. The Finance segment includes the trading and brokerage operations for over-the-counter instruments and exchange rates carried out on the proprietary portfolio, the management of the treasury's interbank operations, and the management of rate and liquidity risk carried out by the bank. The Corporate Center segment consists of the parent company's general management and the corporate bodies, as well as support activities of the governance bodies of its subsidiaries. The Non-Core segment identifies all the non-performing credit positions, probable defaults, performing loans with counterparts that are corporate clients. The company was founded in 1981 and is headquartered in Turin, Italy.

The European Smaller Companies Trust Plc operates as an investment company. Its investment objective is to seek capital growth by investing in smaller and medium sized companies which are quoted, domiciled, listed or have operations in Europe. The company was founded on September 6, 1990 and is headquartered in London, the United Kingdom.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

DeA Capital SpA, a fund of funds, invests in private equity and venture capital funds located in the U.S., Israel, and Europe. It also makes direct co-investments in technology companies.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.